A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo. The secondary objectives include: Evaluating the pharmacokinetic characteristics of HY-2003 after a single administration in humans and obtaining preliminary pharmacokinetic parameters; Evaluating the efficacy of HY-2003 under different doses and dosing frequencies, compared with the positive control and placebo, in the treatment of subjects with moderate to severe submental fat accumulation.

NCT Number	NCT06756490
Lead Sponsor	Sichuan Huiyu Pharmaceutical Co., Ltd Collaborators: Peking Union Medical College Hospital, First Affiliated Hospital Xi'an Jiaotong University
Conditions	Moderate or Severe Submental Fullness
Enrollment	30 participants
Start Date	2024-12-26
Primary Completion	2026-12-06 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-09